Journal
EXPERT REVIEW OF VACCINES
Volume 13, Issue 8, Pages 989-999Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.933078
Keywords
antiviral drugs; enterovirus; Type 1 diabetes; vaccine
Categories
Funding
- Competitive Research Funding of the Tampere University Hospital
- Juvenile Diabetes Research Foundation (JDRF)
- Academy of Finland
- Sohlberg's Foundation
- Sigrid Juselius Foundation
- European Commission
Ask authors/readers for more resources
Type 1 diabetes (T1D) is a chronic disease caused by the destruction of insulin producing -cells in the pancreas. Studies carried out during the past decades have implied that enteroviruses could be an important causative agent. These findings have generated efforts aiming at developing vaccines against these viruses and testing their efficacy against T1D in clinical trials. Extensive work has been carried out to define the serotype of enteroviruses which are linked to T1D and which should be included in the vaccine, and experimental vaccines have been shown to be effective and safe in mouse models. Large-scale studies are currently in progress to increase the confidence in the scientific concept of the enterovirus-diabetes association, paralleling the efforts aimed at starting the clinical development of the vaccine. This review summarizes recent progress in this field and the scenarios regarding this development process.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available